Omar Carranza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Omar Carranza has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Graziela Zibetti Dal Molin
Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil
7 shared publications - Hussein Sweiti
Johnson & Johnson, Spring House, PA
7 shared publications - Marcelo Corassa
A.C. Camargo Cancer Center, Sao Paulo, Brazil
7 shared publications - Shubham Pant
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7 shared publications - Yohann Loriot
Early Drug Development Department, Gustave Roussy, Villejuif, France
7 shared publications - Gunnar Folprecht
National Center for Tumor Diseases Dresden (NCT/UCC), Faculty of Medicine, TU Dresden, Dresden, Germany
6 shared publications
Latest Publications
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
- Open Access
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2501094
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.
Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, is approved for second-line treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations. Primary histology-agnostic analysis from the phase II RAGNAR study (ClinicalTrials.gov identifier: NCT04083976) indicated a clinical benefit with erdafitinib in Broad Panel Cohort (BPC) patients. We present tumor-specific updated efficacy and safety results from the BPC and tumor-agnostic findings from the Exploratory and Pediatric Cohorts of RAGNAR. The Broad Panel, Exploratory, and Pediatric Cohorts enrolled patients with target (selected) FGFR alterations, nontarget FGFR alterations, and any FGFR alterations, respectively. Adults and pediatric patients (6 years and older) with advanced, unresectable, or metastatic disease who progressed after ≥1 prior line of systemic therapy and exhausted standard therapies were eligible. Erdafitinib 3-8 mg once daily (with possible uptitration) was administered orally until disease progression or intolerable toxicity. Objective response rates (ORRs) in the BPC were 10.0% (3 of 30) for high-grade glioma, 26.1% (6 of 23) for non-small cell lung cancer, 28.6% for (2 of 7) low-grade glioma, 31.3% (5 of 16) for breast cancer, 33.3% (5 of 15) for head and neck squamous cell carcinoma, 55.6% (10 of 18) for pancreatic cancer, and 100% (5 of 5) for salivary gland cancer. The ORR was 3.8% (2 of 53) in the Exploratory Cohort. In the Pediatric Cohort (n = 11), there were one responder and seven patients with durable stable disease. Treatment-related adverse events (TRAEs) were consistent with the known safety profile of erdafitinib. Pediatric-specific TRAEs included epiphysiolysis and limb fracture. Encouraging activity was observed for erdafitinib across tumor types in patients with advanced malignancies and selected FGFR alterations who have exhausted treatment options. More limited activity was observed for erdafitnib in the Exploratory Cohort.
- 15 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2501094
Open AccessErdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.
Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, is approved for second-line treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations. Primary histology-agnostic analysis from the phase II RAGNAR study (ClinicalTrials.gov identifier: NCT04083976) indicated a clinical benefit with erdafitinib in Broad Panel Cohort (BPC) patients. We present tumor-specific updated efficacy and safety results from the BPC and tumor-agnostic findings from the Exploratory and Pediatric Cohorts of RAGNAR. The Broad Panel, Exploratory, and Pediatric Cohorts enrolled patients with target (selected) FGFR alterations, nontarget FGFR alterations, and any FGFR alterations, respectively. Adults and pediatric patients (6 years and older) with advanced, unresectable, or metastatic disease who progressed after ≥1 prior line of systemic therapy and exhausted standard therapies were eligible. Erdafitinib 3-8 mg once daily (with possible uptitration) was administered orally until disease progression or intolerable toxicity. Objective response rates (ORRs) in the BPC were 10.0% (3 of 30) for high-grade glioma, 26.1% (6 of 23) for non-small cell lung cancer, 28.6% for (2 of 7) low-grade glioma, 31.3% (5 of 16) for breast cancer, 33.3% (5 of 15) for head and neck squamous cell carcinoma, 55.6% (10 of 18) for pancreatic cancer, and 100% (5 of 5) for salivary gland cancer. The ORR was 3.8% (2 of 53) in the Exploratory Cohort. In the Pediatric Cohort (n = 11), there were one responder and seven patients with durable stable disease. Treatment-related adverse events (TRAEs) were consistent with the known safety profile of erdafitinib. Pediatric-specific TRAEs included epiphysiolysis and limb fracture. Encouraging activity was observed for erdafitinib across tumor types in patients with advanced malignancies and selected FGFR alterations who have exhausted treatment options. More limited activity was observed for erdafitnib in the Exploratory Cohort.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 3 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 3 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 3 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 3 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 1 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Purpose:Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies.Experimental Design:In RAGNAR (phase II, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase IIa study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy [objective response rate (ORR) per blinded independent review committee, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)] and safety analyses.Results:At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n = 66; LUC2001: n = 12), ORR was 55% [95% confidence interval (CI), 43.4–66.4]. The median time to response was 1.7 months; the median DOR, PFS, and OS were 6.9 (95% CI, 4.37–8.61), 8.5 (95% CI, 6.83–9.72), and 18.1 (95% CI, 13.40–24.28) months, respectively. The most common treatment-emergent adverse events (TEAE) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), and palmar–plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation.Conclusions:Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Purpose:Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies.Experimental Design:In RAGNAR (phase II, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase IIa study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy [objective response rate (ORR) per blinded independent review committee, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)] and safety analyses.Results:At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n = 66; LUC2001: n = 12), ORR was 55% [95% confidence interval (CI), 43.4–66.4]. The median time to response was 1.7 months; the median DOR, PFS, and OS were 6.9 (95% CI, 4.37–8.61), 8.5 (95% CI, 6.83–9.72), and 18.1 (95% CI, 13.40–24.28) months, respectively. The most common treatment-emergent adverse events (TEAE) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), and palmar–plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation.Conclusions:Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 2 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 2 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 2 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
Supplementary figure 2 from Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma
- Open Access
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1136-1144
Erdafitinib in Patients with FGFR- Altered Advanced or Metastatic Cholangiocarcinoma
Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies. Experimental Design: In RAGNAR (phase II, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase IIa study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy [objective response rate (ORR) per blinded independent review committee, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)] and safety analyses. Results: At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n = 66; LUC2001: n = 12), ORR was 55% [95% confidence interval (CI), 43.4–66.4]. The median time to response was 1.7 months; the median DOR, PFS, and OS were 6.9 (95% CI, 4.37–8.61), 8.5 (95% CI, 6.83–9.72), and 18.1 (95% CI, 13.40–24.28) months, respectively. The most common treatment-emergent adverse events (TEAE) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), and palmar–plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation. Conclusions: Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1136-1144
Open AccessErdafitinib in Patients with FGFR- Altered Advanced or Metastatic Cholangiocarcinoma
Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies. Experimental Design: In RAGNAR (phase II, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase IIa study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy [objective response rate (ORR) per blinded independent review committee, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)] and safety analyses. Results: At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n = 66; LUC2001: n = 12), ORR was 55% [95% confidence interval (CI), 43.4–66.4]. The median time to response was 1.7 months; the median DOR, PFS, and OS were 6.9 (95% CI, 4.37–8.61), 8.5 (95% CI, 6.83–9.72), and 18.1 (95% CI, 13.40–24.28) months, respectively. The most common treatment-emergent adverse events (TEAE) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), and palmar–plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation. Conclusions: Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.